Search Results - "KELLENBERGER, Laurenz"

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination by Zanini, Elisa, Forster-Gross, Nicole, Bachmann, Felix, Brüngger, Adrian, McSheehy, Paul, Litherland, Karine, Burger, Karin, Groner, Anna C, Roceri, Mila, Bury, Luc, Stieger, Martin, Willemsen-Seegers, Nicole, de Man, Jos, Vu-Pham, Diep, van Riel, Helma W E, Zaman, Guido J R, Buijsman, Rogier C, Kellenberger, Laurenz, Lane, Heidi A

“…Threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) are common essential kinases that collaborate in activating the spindle assembly checkpoint (SAC)…”
Get full text

Antipropionibacterial Activity of BAL19403, a Novel Macrolide Antibiotic by HELLER, Stefanie, KELLENBERGER, Laurenz, SHAPIRO, Stuart

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Polylinker Approach to Reductive Loop Swaps in Modular Polyketide Synthases by Kellenberger, Laurenz, Galloway, Ian S, Sauter, Guido, Böhm, Günter, Hanefeld, Ulf, Cortés, Jesús, Staunton, James, Leadlay, Peter F

“…Multiple versions of the DEBS 1-TE gene, which encodes a truncated bimodular polyketide synthase (PKS) derived from the erythromycin-producing PKS, were…”
Get full text

Activity of the Novel Macrolide BAL19403 against Ribosomes from Erythromycin-Resistant Propionibacterium acnes by DREIER, Jürg, AMANTEA, Eva, KELLENBERGER, Laurenz, PAGE, Malcolm G. P

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Abstract P238: Derazantinib, an inhibitor of fibroblast growth factor receptors 1-3, synergises with paclitaxel in pre-clinical gastric tumor models by McSheehy, Paul M., El Shemerly, Mahmoud, Bachmann, Felix, Kellenberger, Laurenz, Lane, Heidi

“…Background: Derazantinib (DZB) is an oral fibroblast growth factor receptor (FGFR) inhibitor with clinical activity in intrahepatic cholangiocarcinoma. Kinase…”
Get full text

The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR by McSheehy, Paul, Bachmann, Felix, Forster-Gross, Nicole, El Shemerly, Mahmoud, Roceri, Mila, Kellenberger, Laurenz, Lane, Heidi A

“…Abstract only 421 Background: DZB is an oral small-molecule Fibroblast Growth Factor Receptor 1/2/3 inhibitor (FGFRi) with clinical activity in…”
Get full text

The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo by McSheehy, Paul M.J., Forster-Gross, Nicole, El Shemerly, Mahmoud, Bachmann, Felix, Roceri, Mila, Hermann, Norbert, Spickermann, Jochen, Kellenberger, Laurenz, Lane, Heidi A.

“…Derazantinib (DZB) is an inhibitor of fibroblast growth factor receptors 1–3 (FGFR1–3), with additional activity against colony-stimulating-factor-1 receptor…”
Get full text

The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo by McSheehy, Paul M.J., Forster-Gross, Nicole, El Shemerly, Mahmoud, Bachmann, Felix, Roceri, Mila, Hermann, Norbert, Spickermann, Jochen, Kellenberger, Laurenz, Lane, Heidi A.

“…Derazantinib (DZB) is an inhibitor of fibroblast growth factor receptors 1–3 (FGFR1–3), with additional activity against colony-stimulating-factor-1 receptor…”
Get full text

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma by Braun, Stephan, McSheehy, Paul, Litherland, Karine, McKernan, Phil, Forster-Gross, Nicole, Bachmann, Felix, El-Shemerly, Mahmoud, Dimova-Dobreva, Miryana, Polyakova, Inessa, Häckl, Manuel, Zhou, Ping, Lane, Heidi, Kellenberger, Laurenz, Engelhardt, Marc

“…This review evaluates the clinical role of fibroblast growth factor receptor 2 (FGFR2) inhibition with derazantinib in patients with intrahepatic…”
Get more information

Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models by El Shemerly, Mahmoud, Zanini, Elisa, Lecoultre, Marc, Walker, Paul R., Kellenberger, Laurenz, Lane, Heidi A., McSheehy, Paul M.J.

“…Derazantinib (DZB) is an inhibitor of the fibroblast growth factor receptors 1–3 (FGFRi) with similar potency against colony-stimulating factor receptor-1…”
Get full text

Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer by McSheehy, Paul, Bachmann, Felix, Forster-Gross, Nicole, Lecoultre, Marc, Shemerly, Mahmoud El, Roceri, Mila, Reinelt, Stefan, Kellenberger, Laurenz, Walker, Paul R, Lane, Heidi

“…Background: DZB is an oral small-molecule Fibroblast Growth Factor Receptor 1/2/3 inhibitor (FGFRi) with clinically relevant activity in FGFR2-fusion…”
Get full text

Abstract 5501: Derazantinib, an FGFR1-3 inhibitor, inhibits CSF1R in macrophages and tumor cell lines, and synergizes with a PDL1-antibody in an FGFR-driven murine syngeneic model by Shemerly, Mahmoud EL, Kellenberger, Laurenz, Zanini, Elisa, Lane, Heidi, McSheehy, Paul

“…Introduction: Derazantinib (DZB), an inhibitor of the fibroblast growth factor receptors 1-3 (FGFR1-3), is in phase-2 clinical trials for cholangiocarcinoma,…”
Get full text

Stemming the tide? by Page, Malcolm GP, Kellenberger, Laurenz

Get full text

Abstract 5645: BAL0891: A novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity by Lane, Heidi A., Bachmann, Felix, Zanini, Elisa, McSheehy, Paul, Litherland, Karine, Forster-Gross, Nicole, Bury, Luc, Vu-Pham, Diep, de Man, Jos, van Riel, Wilhelmina E., Zaman, Guido JR, Buijsman, Rogier C., Kellenberger, Laurenz

“…Background: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1). These kinases collaborate in activating the mitotic…”
Get full text

Abstract 5646: BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division by Zanini, Elisa, Forster-Gross, Nicole, Bachmann, Felix, Willemsen-Seegers, Nicole, de Man, Jos, Zaman, Guido J., Buijsman, Rogier C., Groner, Anna, Roceri, Mila, Burger, Karin, McSheehy, Paul, Kellenberger, Laurenz, Lane, Heidi A.

“…Background: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1). These kinases collaborate in activating the mitotic…”
Get full text

Stemming the tide?: Advances in antibiotic discovery and development in the face of emerging resistance and financial constraint by Page, Malcolm GP, Kellenberger, Laurenz

Get full text

Abstract C229: BAL27862: A novel anticancer agent which dissociates microtubules and creates a distinct cellular phenotype by Bachmann, Felix, Burger, Karin, Pohlmann, Jens, Kellenberger, Laurenz, Lane, Heidi

“…Background: BAL27862 is a synthetic small molecule potently inducing apoptosis in cancer cells due to tubulin depolymerization. BAL27862 has a broad in vitro…”
Get full text

Propenylamide and propenylsulfonamide cephalosporins as a novel class of anti-MRSA β-lactams by Pohlmann, Jens, Vasilevich, Natalya I., Glushkov, Andrei I., Kellenberger, Laurenz, Shapiro, Stuart, Caspers, Patrick, Page, Malcolm G.P., Danel, Franck

“…Novel C(3) propenylamide and propenylsulfonamide cephalosporins have been synthesized and tested for their ability to inhibit the penicillin-binding protein 2′…”
Get full text

Propenylamide and propenylsulfonamide cephalosporins as a novel class of anti-MRSA b-lactams by Pohlmann, Jens, Vasilevich, Natalya I, Glushkov, Andrei I, Kellenberger, Laurenz, Shapiro, Stuart, Caspers, Patrick, Page, Malcolm GP, Danel, Franck

“…Novel C(3) propenylamide and propenylsulfonamide cephalosporins have been synthesized and tested for their ability to inhibit the penicillin-binding protein 2'…”
Get full text

Elucidation of the in vitro metabolic profile of stable isotope labeled BAL19403 by accurate mass capillary liquid chromatography/quadrupole time-of-flight mass spectrometry and isotope exchange by Wind, Mathias, Gebhardt, Klaus, Grunwald, Helge, Spickermann, Jochen, Donzelli, Massimiliano, Kellenberger, Laurenz, Muller, Marc, Fullhardt, Pascal, Schmitt-Hoffmann, Anne, Schleimer, Michael

“…The in vitro metabolic pattern of BAL19403, a novel macrolide antibiotic, was investigated by capillary liquid chromatography/quadrupole time‐of‐flight mass…”
Get full text